Case Report: COVID-19-associated Refractory Thrombotic Thrombocytopenic Purpura Complicated with Guillain-Barré Syndrome

Overview

Journal Front Neurol

Specialty Neurology

Date 2023 Jun 9

PMID 37292131

Authors

Rui Zhou

Shenjian Chen

Qinghua Luo

Xinyue Zhang

Fang Li

Wei Huang

Zhiyong Sheng

Affiliations

Soon will be listed here.

Abstract

Thrombotic thrombocytopenic purpura (TTP), a rare and lethal thrombotic microangiopathy, is an autoimmune disease that can be triggered by viral infections such as COVID-19. This condition is characterized by hemolytic microangiopathy, thrombocytopenia, and neurologic alterations, possibly accompanied by fever and renal damage. Moreover, more than 220 patients with Guillain-Barré syndrome (GBS) have been reported in association with the COVID-19 infection. In this report, we present a case of a patient who developed refractory TTP complicated by GBS following a SARS-CoV-2 infection. We aimed to highlight the importance of accurately diagnosing neurological complications associated with a COVID-19 infection and to demonstrate our strategies for treating a patient with COVID-19 infection-related refractory TTP complicated by GBS.

References

Mancini I, Baronciani L, Artoni A, Colpani P, Biganzoli M, Cozzi G . The ADAMTS13-von Willebrand factor axis in COVID-19 patients. J Thromb Haemost. 2020; 19(2):513-521. PMC: 7753796. DOI: 10.1111/jth.15191. View

Chaudhary H, Nasir U, Syed K, Labra M, Reggio C, Aziz A . COVID-19-Associated Thrombotic Thrombocytopenic Purpura: A Case Report and Systematic Review. Hematol Rep. 2022; 14(3):253-260. PMC: 9397065. DOI: 10.3390/hematolrep14030035. View

Scully M, Cohen H, Cavenagh J, Benjamin S, Starke R, Killick S . Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. Br J Haematol. 2007; 136(3):451-61. DOI: 10.1111/j.1365-2141.2006.06448.x. View

Dhingra G, Maji M, Mandal S, Vaniyath S, Negi G, Nath U . COVID 19 infection associated with thrombotic thrombocytopenic purpura. J Thromb Thrombolysis. 2021; 52(2):504-507. PMC: 8075832. DOI: 10.1007/s11239-021-02452-0. View

Hindilerden F, Yonal-Hindilerden I, Akar E, Kart-Yasar K . Covid-19 associated autoimmune thrombotic thrombocytopenic purpura: Report of a case. Thromb Res. 2020; 195:136-138. PMC: 7335418. DOI: 10.1016/j.thromres.2020.07.005. View

Lemiale V, Valade S, Mariotte E . Unresponsive Thrombotic Thrombocytopenic Purpura (TTP): Challenges and Solutions. Ther Clin Risk Manag. 2021; 17:577-587. PMC: 8185636. DOI: 10.2147/TCRM.S205632. View

van den Berg B, Walgaard C, Drenthen J, Fokke C, Jacobs B, van Doorn P . Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol. 2014; 10(8):469-82. DOI: 10.1038/nrneurol.2014.121. View

Benjamin R . A conceptual framework for managing iTTP. Blood. 2021; 137(14):1845-1846. DOI: 10.1182/blood.2021011007. View

Nicolotti D, Bignami E, Rossi S, Vezzani A . A case of thrombotic thrombocytopenic purpura associated with COVID-19. J Thromb Thrombolysis. 2021; 52(2):468-470. PMC: 7778714. DOI: 10.1007/s11239-020-02362-7. View

10.

Conway E, Mackman N, Warren R, Wolberg A, Mosnier L, Campbell R . Understanding COVID-19-associated coagulopathy. Nat Rev Immunol. 2022; 22(10):639-649. PMC: 9362465. DOI: 10.1038/s41577-022-00762-9. View

11.

Joly B, Darmon M, Dekimpe C, Dupont T, Dumas G, Yvin E . Imbalance of von Willebrand factor and ADAMTS13 axis is rather a biomarker of strong inflammation and endothelial damage than a cause of thrombotic process in critically ill COVID-19 patients. J Thromb Haemost. 2021; 19(9):2193-2198. PMC: 8420340. DOI: 10.1111/jth.15445. View

12.

Merrill J, Erkan D, Winakur J, James J . Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications. Nat Rev Rheumatol. 2020; 16(10):581-589. PMC: 7391481. DOI: 10.1038/s41584-020-0474-5. View

13.

Wynick C, Britto J, Sawler D, Parker A, Karkhaneh M, Goodyear M . Validation of the PLASMIC score for predicting ADAMTS13 activity <10% in patients with suspected thrombotic thrombocytopenic purpura in Alberta, Canada. Thromb Res. 2020; 196:335-339. DOI: 10.1016/j.thromres.2020.09.012. View

14.

Shoraka S, Brito Ferreira M, Mohebbi S, Ghaemi A . SARS-CoV-2 Infection and Guillain-Barré Syndrome: A Review on Potential Pathogenic Mechanisms. Front Immunol. 2021; 12:674922. PMC: 8141918. DOI: 10.3389/fimmu.2021.674922. View

15.

Magro C, Mulvey J, Berlin D, Nuovo G, Salvatore S, Harp J . Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases. Transl Res. 2020; 220:1-13. PMC: 7158248. DOI: 10.1016/j.trsl.2020.04.007. View

16.

Bomhof G, Mutsaers P, Leebeek F, Te Boekhorst P, Hofland J, Croles F . COVID-19-associated immune thrombocytopenia. Br J Haematol. 2020; 190(2):e61-e64. PMC: 7276755. DOI: 10.1111/bjh.16850. View

17.

Sayani F, Abrams C . How I treat refractory thrombotic thrombocytopenic purpura. Blood. 2015; 125(25):3860-7. PMC: 4473115. DOI: 10.1182/blood-2014-11-551580. View

18.

Jamme M, Rondeau E . The PLASMIC score for thrombotic thrombocytopenic purpura. Lancet Haematol. 2017; 4(4):e148-e149. DOI: 10.1016/S2352-3026(17)30024-8. View

19.

Khan F, Sharma P, Pandey S, Sharma D, V V, Kumar N . COVID-19-associated Guillain-Barre syndrome: Postinfectious alone or neuroinvasive too?. J Med Virol. 2021; 93(10):6045-6049. PMC: 8426929. DOI: 10.1002/jmv.27159. View

20.

Zhu W, Li K, Cui T, Yan Y . Detection of anti-ganglioside antibodies in Guillain-Barré syndrome. Ann Transl Med. 2023; 11(7):289. PMC: 10116427. DOI: 10.21037/atm-20-2285. View